Abstract
Prolonged usage of antifungal azoles which target enzymes involved in lipid biosynthesis invariably leads to the development of multi-drug resistance (MDR) in Candida albicans. We had earlier shown that membrane lipids and their fluidity are closely linked to the MDR phenomenon. In one of our recent studies involving comparative lipidomics between azole susceptible (AS) and azole resistant (AR) matched pair clinical isolates of C. albicans, we could not see consistent differences in the lipid profiles of AS and AR strains because they came from different patients and so in this study, we have used genetically related variant recovered from the same patient collected over a period of 2-years. During this time, the levels of fluconazole (FLC) resistance of the strain increased by over 200-fold. By comparing the lipid profiles of select isolates, we were able to observe gradual and statistically significant changes in several lipid classes, particularly in plasma membrane microdomain specific lipids such as mannosylinositolphosphorylceramides and ergosterol, and in a mitochondrial specific phosphoglyceride, phosphatidyl glycerol. Superimposed with these quantitative and qualitative changes in the lipid profiles, were simultaneous changes at the molecular lipid species levels which again coincided with the development of resistance to FLC. Reverse transcriptase-PCR of the key genes of the lipid metabolism validated lipidomic picture. Taken together, this study illustrates how the gradual corrective changes in Candida lipidome correspond to the development of FLC tolerance. Our study also shows a first instance of the mitochondrial membrane dysfunction and defective cell wall (CW) in clinical AR isolates of C. albicans, and provides evidence of a cross-talk between mitochondrial lipid homeostasis, CW integrity and azole tolerance.
Introduction
The phenomenon of Candida cells acquiring multidrug resistance (MDR) is common. This however hampers their successful chemotherapy [1]–[4]. The Candida species infections by and large have been controlled by using the systemic azole drug fluconazole (FLC), and other topical azole and polyene drugs. The excessive use of FLC has however, resulted in the emergence of azole-resistant strains of Candida species [5]–[8]. Candida albicans as well as non-albicans species have evolved a variety of mechanisms to develop MDR to common antifungals. Reduced intracellular accumulation of drugs (due to rapid efflux) is one of the most prominent mechanisms of resistance in Candida cells. Accordingly, clinical azole resistant isolates of C. albicans display transcriptional activation of genes, encoding ATP Binding Cassette (ABC) multidrug transporter proteins CaCdr1p or CaCdr2p or Major Facilitator Super family (MFS) efflux pump protein CaMdr1p [5]–[8].
In C. albicans, lipids in addition to being the structural and metabolic components of yeast cells also play an important role in the frequently observed MDR. For example, CaCdr1p shows selectivity towards membrane recruitment and prefers membrane raft microdomains for its localization within plasma membrane [9]. There are close interactions between raft constituents such as ergosterol and sphingolipids (SLs), and disruption of these results in altered drug susceptibilities [10], [11]. Thus, any change in ergosterol composition by disruption of ERG genes, or change in SL composition by disruption of its biosynthetic genes, leads to improper surface localization of CaCdr1p [9]. Interestingly, MFS transporter CaMdr1p shows no such selectivity towards raft lipid constituents and remains fully membrane localized and functional in cells where SL or ergosterol biosynthesis is compromised [9]. There are also instances where common regulation of MDR and lipid metabolism genes have been observed [12], [13]. Changes in the status of membrane lipid phase (or membrane fluidity) and asymmetry also seem to affect azole resistance in C. albicans [14]. Taken together, MDR in C. albicans is closely linked to the membrane lipid composition. The overall drug susceptibility of a cell appears to be an interplay of membrane lipid environment, drug diffusion and extrusion [15]. Thus, it is quite apparent that lipids in some way or the other contribute to the development of resistant phenotype. However, the exact sets of changes that occur in the lipid composition leading to the resistant phenotype are not completely understood.
In our previous study, we had used a combination of high throughput mass spectrometry and statistical validation methods to analyze the lipidome of eight pairs of genetically matched clinical azole-susceptible (AS) and azole-resistant (AR) isolates of C. albicans [16]. We observed that although each AR isolate was similar with regard to displaying high MICs to drugs, each had a distinct lipid imprint. That study also revealed that each AR isolate was rather unique in terms of its lipidome, and that there were very few common lipid changes among AR isolates. The AS/AR matched isolates used therein were obtained from different patients (variable host environment); hence, the typical metabolic state of each AR isolate was not surprising [16]. In the present study, we have used a single clinical isolate of C. albicans recovered from an HIV-patient over a period of 2 years of FLC therapy during which time the level of FLC tolerance of the strain increased over 200-fold. Since these isolates were collected from a single patient, any possibility of variation in host environment and its effect on metabolic state of cells was minimized. We have subjected these isolates to high throughput MS-based platform and have performed detailed lipid profiling and compared the lipidomes of these sequential isolates of C. albicans. Our study provides a comprehensive picture of lipidomic changes which occur as the susceptible isolate develops tolerance to FLC. The spectrum of about 242 molecular species allowed us to identify and show how gradually their composition changed with increasing tolerance to FLC. The changes in ergosterol and SL-components of membrane microdomains, and in mitochondrial specific lipid phosphatidyl glycerol (PG) are most noteworthy. Our study shows an occurrence of a cross-talk between mitochondria, cell wall (CW) and Candida Drug Resistance (CDR) genes in the clinical scenario, in a sequential and related C. albicans isolate recovered from a single patient undergoing azole therapy.
Results
Shotgun screening of Candida Lipidome
The availability of genetically related variants recovered over a period of time from the same host enabled us to make a direct comparison of changes in lipidomes occurring in parallel to the development of resistance to FLC. These 17 isolates (TW1-17) which have been recovered by White's group have previously been characterized to show overexpression of CDR genes associated with the development of tolerance to FLC [17]. Of note, out of total isolates, we have chosen 6 isolates from 3 different time points of FLC therapy to cover the entire range of levels of FLC tolerance. Based on the MICs, our selection included: TW1 and TW2 which were highly susceptible to FLC (MIC80 ≤4µM), TW8 and TW9 had intermediate level of susceptibility to FLC (MIC80 ≤32µM) while TW16 and TW17 were highly tolerant to FLC (MIC80 >125µM). Before embarking upon lipidome analysis, we re-evaluated some of their phenotypic and molecular characteristics in these selected isolates which matched well with their published properties (Figure S1). For lipidome analysis, these selected isolates were harvested in the exponential growth phase and their total lipids were extracted as described in Materials and Methods [18]. The extracted lipids were subjected to ESI-MS/MS by direct infusion of the lipid extracts. The total amount of lipid was quantified as total normalized mass spectral signal of PGL (phosphoglycerides) + SL + SE (Sterol ester). The lipid content was found to range between 1018 to 1136 nmol per mg dry lipid weight in the Candida isolates analyzed (Sheet S1, worksheet 2).
Although, we determined lipids to their absolute amounts (as total normalized mass spectral signal of PGL + SL + SE), we have used the mole percentages (as % of total normalized mass spectral signal of PGL + SL + SE) for data analysis, which have lower standard deviation. By employing MS analysis, nine major PGLs classes which included phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), phosphatidyl inositol (PI), phosphatidyl serine (PS), PG, phosphatidic acid (PA), lysoPC, lysoPE and lysoPG were targeted. Additionally, the lipid molecular species were identified by mass of the head group plus the mass of the intact lipid, allowing determination of the number of C atoms and double bonds in the acyl chain(s) of PGLs. The PGLs were quantified in relation to internal standards of the same lipid class. This procedure is known to provide accurate quantification because various molecular species of the same lipid class (here, the internal standard and other species) produce very similar amounts of mass spectral signal after electrospray ionization [19]. Our MS analysis also included four major groups of SLs, ceramides (CER), inositolphosphorylceramide (IPC), mannosylinositolphosphorylceramide (MIPC), mannosyldiinositolphosphorylceramide (M(IP)2C) and their relative amounts were determined. These observed lipid differences were also validated by evaluating select responsible genes of lipid metabolic pathways by reverse transcriptase PCR (RT-PCR) and by employing high performance – thin layer chromatography (HP-TLC). Initially, we did perform RT-PCR of some genes using all the isolates (Figure S1C) and found that the gene expression pattern was quite similar between isolate TW16 and TW17, and TW1 and TW2. Therefore for a direct comparison between most susceptible and tolerant isolate, RT-PCR was performed only with TW1 and TW17 isolates (discussed below).
Most tolerant isolates have high levels of sterol esters
Sterols were identified and quantified as SEs, as described in methods (Text S1). SEs ranged between 2.8 – 15.8% (% of total normalized mass spectral signal of PGL + SL + SE) which were accumulated up to 3 folds in TW16 and TW17, as compared to the less tolerant strain isolated at an earlier time point (Figure 1B). This accumulation of SEs in TW16 and TW17 was evident by a simultaneous increase in intermediate metabolites of sterol biosynthetic pathway and ergosterol ester, which was accumulated up to ∼5 fold (Figure 1A). While examining the FA composition of SEs, we found that all, C16:1, C16:0, C18:3, C18:2, C18:1 and C18:0 –FA containing SEs were elevated up to ∼4 fold in TW16 and TW17 as compared to the other FLC susceptible isolates (Sheet S1, worksheet 4). Using RT-PCR, we found that ergosterol biosynthetic pathway genes are upregulated in TW17 isolate as compared to susceptible TW1 (Figure 1C). An upregulated ARE2 (an acyl CoA: sterol acyltransferase which regulates free sterol esterification) correlated well with the fact that most of the sterol predominantly accumulates as SEs in TW17 isolate (Figure 1C). Of note, we also noticed an unexplained difference between TW1 and TW2 with regards to the levels of ERG11 expression (Figure S1C).
MIPC content is depleted in resistant isolates
In C. albicans, it has been demonstrated that the interactions between membrane SLs and ergosterol are critical, and reduction in the content of either results in enhanced susceptibilities to drugs [9]–[11]. Therefore, to evaluate the impact of FLC exposure on SLs in TW isolates, we performed a detailed analysis as described in Text S1. We observed a trend of depletion in SL content in TW17 isolate in comparison to its susceptible counterpart TW1; however, this change was statistically not significant (Figure 2B). Using MS analysis, we further analyzed four major classes of SLs which included CER (detected as α-hydroxy phytoceramide), IPC, MIPC and M(IP)2C (Figure 2A). While the total SLs content did not vary significantly, MIPC was depleted up to 3.4 folds in TW17 as compared to its susceptible counterparts (Figure 2A). Of note, though IPC was accumulated by 1.5 fold in TW17 compared to TW1, but this difference was statistically not significant. M(IP)2C was below detection limits in TW17 isolate. We validated some of the genes of SL metabolism by semi-quantitative RT-PCR which revealed an overexpression of LCB4 (D-erythro-sphingosine kinase) and ISC1 (inositol phosphosphingolipidphospholipase C); however, statistically these changes were not significant (Figure 2C).
Molecular species are responsive to the development of FLC tolerance
Based on the fatty acid (FA) composition and their positional distribution, each lipid class is sub-categorized into its molecular species [20]. A large number of these molecular lipid species and their numerous interactions with proteins and other lipids in yeasts provide flexibility in balancing their lipid composition in a variety of cellular processes [20]. Since majority of the major lipid classes were not significantly changed in FLC tolerant isolates, we evaluated that FLC exposure might lead to changes in the content and composition of different lipid molecular species. Therefore, we quantified the molecular lipid species by MS analysis of the extracts of TW isolates and detected molecular lipid species belonging to three major lipid groups (PGL, SL, and SE; see Sheet S1, worksheet 2). We could determine the abundance of over 242 species belonging to PGL, SL and SEs (Table S1 depicts changes only in the molecular species which were statistically significant) and observed that while adapting to the increasing FLC concentration, TW isolates show significant differences in the molecular species composition. For example, when we compared TW1 vs TW2, TW2 vs TW8, TW8 vs TW9, TW9 vs TW16 and TW16 vs TW17, the number of molecular species that undergo a significant change are about 60, 44, 28, 68 and 27, respectively. When we compared TW1 (most susceptible) with TW17 (most resistant), about 103 molecular lipid species of different lipid classes were found to be significantly variable (Sheet S1 (worksheet 3) and Table S1).
Notably, the changes in the molecular lipid species were gradual and correlated with the threshold of FLC tolerance among TW isolates. That each isolate has a typical molecular species profile was evident from principal component analysis (PCA) and hierarchal cluster analysis where these isolates could be separated as different clusters (Figure S2, Text S2 and Table S5). Moreover, this large scale lipid remodeling results in higher membrane order in FLC adapted strains as was evident from fluorescence polarization studies where TW17 has high P–value and low unsaturation index (both implying high membrane order) (Figure S3A and S3B).
Long chain FA (LCFA) and odd chain FA levels respond to the development of FLC tolerance
A thorough examination of the molecular lipid species imprints of TW isolates revealed that there is accumulation of long chain FA containing ≥36-carbon PGL species, and depletion in ≤34-carbon containing PGL species with the increasing tolerance to FLC. This pattern was consistent among all PGL classes, and reflected FA chain lengths remodeling to maintain membrane composition in response to FLC stress (Table S2).
We had earlier detected odd chain FA containing lipid species in various Candida species and in various AS/AR isolates to show that 31-, 33-, 35- and 37- carbon containing PGL species comprise the overall pool of the odd chain FAs in Candida [21]. Interestingly, we observed a depletion of odd chain FA containing PGL species with increasing tolerance to FLC exposure (Figure 3). These changes were more prominent in PC, PE, PI and PS species (Table S3). The large scale compositional changes in FAs of the PGL species are probably the result of the changes in the gene expression or changes in the levels of enzymes of FA metabolism (Table 1).
Table 1. Gene expression analysis of various genes between TW1 and TW17.
Category | Gene name | TW1 | TW17 | p-value |
PL metabolism | PSD1 | 2.27±0.38 | 3.74±0.52 | 0.07 |
PSD2 | 1.47±0.15 | 3.34±0.38 | 0.02 | |
PEL1 | 1.80±0.57 | 1.85±0.65 | 0.48 | |
CDS1 | 0.90±0.10 | 0.78±0.03 | 0.11 | |
CRD1 | 0.87±0.08 | 1.07±0.07 | 0.09 | |
Membrane pumps | CDR1 | 1.45±0.09 | 2.43±0.16 | 0.02 |
CDR2 | 1.43±0.01 | 2.44±0.07 | 0.00 | |
MDR1 | 2.26±0.11 | 2.82±0.01 | 0.02 | |
FA metabolism | FAS1 | 0.70±0.02 | 0.73±0.03 | 0.26 |
FAS2 | 4.68±0.01 | 5.89±0.08 | 0.00 | |
orf19.6443 | 1.09±0.02 | 0.94±0.04 | 0.03 | |
EC11 | 2.76±0.11 | 3.05±0.04 | 0.06 | |
POT1-2 | 6.83±0.18 | 20.6±1.00 | 0.00 | |
orf19.3859 | 0.99±0.07 | 1.53±0.18 | 0.05 |
Transcript levels were determined by RT-PCR as described in Methods. The data represents relative amplification to ACT1. Values are means ± SD (n = 3) along with the p-values.
Mitochondrial PG levels are lower in resistant isolates
Our method could detect six major PGLs in the abundance order PC>PE>PI>PS>PA>PG, which did not change between the AS and AR pairs (Figure 4). PC, PE and PI accounted for almost 80% PGLs in all the isolates. As shown in figure 4 (Inset A), contents of mitochondrial lipid PG decreased by as much as 1.4 fold in TW17 as compared to most susceptible TW1. However, MS based lipidome analysis and HP-TLC revealed that there was no statistically significant change in most of the other PGLs (Figure 4). PG is metabolic precursor of cardiolipin (CL) which is a major mitochondrial anionic phospholipid (PL) with important functions in promoting cell growth, anaerobic metabolism and mitochondrial biogenesis [22]. We observed that a depletion of PG levels was also associated with a simultaneous decrease in CL levels (Figure 4, inset B). PGLs composition was also validated by HP-TLC which showed a drop in PG and CL in most FLC tolerant TW17 isolate (Figure 4, inset B). It should be noted that we could only measure CL content by HP-TLC.
However, the RT-PCR data did not show any significant changes in the transcript levels of CDS1 (a CDP-diglyceride synthetase) PEL1 (a phosphatidylglycerolphosphate synthase) and CRD1 (CL synthase) between TW1 and TW17 isolates (Table 1). Of note, we observed an apparent gradual decrease in CL levels with increasing FLC tolerance, but the overall ratio of CL/PG was maintained in most of the isolates. For example, in TW17 the CL is decreased by ∼1.6 fold but the ratio of CL/PG is similar to TW16 where the contents of CL are rather higher, compared to TW1 isolate. Apparently, the required CL levels necessary for proper functioning of mitochondria are largely maintained and it is the anionic-PG, whose imbalanced level most likely affects the mitochondrial membrane (discussed below).
Decreased PG level leads to compromised mitochondrial membrane and CW integrity
We evaluated if reduction in the mitochondrial specific lipid PG would affect mitochondrial integrity. For this, we used cell-permeant mitochondrion-selective dye Mito Tracker Red CMxROS which is a good indicator of mitochondrial integrity [23], [24]. Interestingly, compared to TW1, we observed ∼40% decrease in mean fluorescent intensity in binding of the probe in TW17 isolate (Figure 5A, 5B and 5C). Of note, no visual difference in the mitochondrial integrity could be deduced by confocal microscopy of labeled TW1 and TW17 isolates (Figure 5D). Moreover, the TW17 did neither show much alteration in mitochondrial respiratory activity as was deduced from their ability to grow normally on non-fermentable carbon sources or at elevated temperatures (data not shown), nor did the TW17 show any defects in ROS generation as indicated by flow cytometry and confocal microscopy using DC-FDA (molecular probes) (data not shown).
The CW integrity is linked to mitochondria and PL homeostasis [25], however, the link between the mitochondria, CW integrity and azole resistance is largely unexplored in C. albicans. Interestingly, we observed that TW17 isolate was susceptible to the CW perturbing agents SDS, Congo red and Calcofluor white (Figure 6A and 6B). The compromised CW integrity of TW17 isolate could further be confirmed by increased passive diffusion and accumulation of otherwise impermeate fluorescent PI (Figure 6C and 6D).
A correlation with PG content with CW integrity and mitochondrial functions was further evident from our other data. We used two other matched pair clinical isolates of C. albicans, Gu4/Gu5 and DSY347/DSY289 (where Gu5 and DSY289 are resistant to drugs). Both Gu5 and DSY289 had lowered PG levels (∼1.5 and ∼6.4 fold, respectively) as well as compromised CW as compared to their susceptible counterparts (Figure 7A and B).
In another matched pair DSY544/DSY775, where the PG content was higher in resistant DSY775 as compared to its sensitive counterpart DSY544 (Figure 7B), no CW defect was evident (Figure 7A). In the DSY294/DSY296 isogenic pair where PG content did not change between sensitive DSY294 and resistant DSY296 (Figure 7B) also had no evident CW damage (Figure 7A). Notably, we could not see consistent differences in the lipid profiles of these AS and AR pairs (CL levels), probably because they come from different patients, however, a correlation with PG content with CW integrity and mitochondrial functions was further evident from our other data.
Discussion
Prolonged exposure of C. albicans to FLC allows cells to develop tolerance to higher concentrations of the drug [5]–[8]. Hence, AR cells display considerably decreased susceptibility to the drugs (high MICs). An overexpression of efflux pump proteins like Cdr1, Cdr2, and Mdr1 is one of the main contributors of azole resistance, which necessitates several compensatory adaptive changes, that includes alterations in lipid metabolism of Candida [5]–[8], [12], [13], [17]. The importance of lipids in the physiology of Candida including in MDR is well established [9]–[11], [14]–[16]. However, exactly how lipids adapt or change, are some of the aspects which are not well understood.
Previously, in an attempt to evaluate the impact of FLC on the lipid regulatory circuitry behind MDR in C. albicans, we had performed a comparative lipidomics of AS and AR clinical isolates of C. albicans isolated from different patients [16]. In the present study, to minimize any variations due to host/pathogen niches, we have used sequential isolates earlier isolated by Ted White's group, from a single HIV-infected patient who was on FLC therapy for over a period of 2 years [17]. In this TW series of 17 isolates (TW1-17), each isolate represents an isogenic precursor parent of the next isolate. A comparative snap shot lipidomic status of selected sequential AR isolates of C. albicans gave interesting insights.
Membrane raft specific lipids are selectively affected in AR isolates
In C. albicans, ergosterol which is predominantly localized within microdomains “lipid raft”, is involved in many physiological functions and provides surface localization platform for membrane proteins [9]–[11], [26], [27]. Thus, the observed raised levels of ergosterol in highly resistant TW16 and 17 (validated by RT-PCR) (Figure 1) could be linked to an overexpressed level of Cdr1 protein, since it is preferentially localized within the lipid raft microdomains [9]. Recently, Zhang et al. demonstrated that ergosterol levels are required in V-ATPase function which forms the cellular basis of azole toxicity in C. albicans [28]. Further, the mammalian presynaptic serotonin transporter (SERT) is functionally overexpressed only in the presence of cholesterol [29].
In contrast to ergosterol, there was a marked depletion of another major constituent of membrane microdomains. One of the complex SL members, MIPC contents was significantly lower in TW16/17 isolate as compared to TW1 (Figure 2A). This depletion in MIPC content may appear odd for maintenance of the raft domain. However, there are instances to show that a minimum level of SL is sufficient to maintain the raft integrity and efflux function [30]. Therefore, it could be argued that observed depletion of SLs which is probably the result of azoles induced compensatory changes in TW17 remains within its critical limits and along with the raised ergosterol, continues to provide optimal platform to maintain the functionality of overproduced Cdr1 protein.
Azole resistance necessitates remodeling of molecular species of lipids
In yeasts, although structural classes of lipids are limited, they have the potential to generate up to several thousand different molecular species to bring in diversity in lipid composition [20]. Our present results clearly demonstrate that exposure of C. albicans to FLC triggers massive remodeling of molecular lipid species in TW isolates (Table S1, Sheet S1, worksheet 2 and 3). The fact that ∼103 molecular lipid species were found to be significantly variable between TW1 and TW17 implies that there is large scale remodeling of molecular lipid species while the isolate gradually adapts to FLC toxicity. Since the intracellular drug concentration is dependent not only on active drug efflux, but also on the rate of its import, the order of the membrane lipid bilayer core becomes an important determinant in the development of drug resistance [14], [15], [26].
AR isolates display an increase in LCFA and depletion in odd chain FAs
The LCFA's are functionally very relevant in bacterial models but in yeasts like C. albicans these are poorly understood [21], [31], [32]. In C. albicans, it is quite understandable that the membrane PLs might incorporate FAs of varying length and saturation to maintain the optimal membrane order [33]. Precisely, we observed an accumulation of LCFA containing ≥36-carbon PGL species at an expense of ≤34-carbon containing PGL species, with the increasing FLC tolerance (Table S2). Since the FAs with lesser chain lengths, and higher unsaturation are less rigid [34], therefore an increased pool of LCFA (of ≥36-carbon containing PGLs) might directly be contributing to maintain the high order of the membrane.
Notably, we also observed a progressive depletion of typical odd chain FA containing PGLs with the increasing tolerance to FLC (Figure 3 and Table S3). Although this study for the first time points towards odd chain FA containing PGLs role in drug tolerance adapting mechanisms of pathogenic C. albicans, a complete understanding of the physiological relevance of it requires further validation. If explored in detail, possibly like in animal models of environmental and food web studies, these odd chain FAs could serve as useful biomarkers for C. albicans drug resistance [35]–[37].
Together, changes like increased pool of LCFA's and depletion of odd-chain FAs along with variations in molecular lipid species are the reflection of close knit maintenance of membrane lipid homeostasis. Of note, the fact that both odd chain FAs and very-LCFA (generally up to 22 carbons) are well established features of plant lipids [36], [38], the presence of these lipids in human pathogenic C. albicans is of great evolutionary significance [21].
A change in PG and CL in AR isolates points a link between mitochondria and CW integrity
Recently, mitochondria have been identified as an important contributor to virulence and drug tolerance of human fungal pathogens [39]–[43]. For example, mitochondrial mutants of yeast display altered drug susceptibility to drugs, particularly those which target cell membranes, such as the azoles and the polyenes [25], [41], [43], [44]–[47]. Apparently mitochondrial function in membrane lipid homeostasis is the common denominator underlying the observed effects of mitochondria in drug tolerance and CW integrity. The mechanistic details, particularly how these two pathways are linked, are far from understood. The observed changes in the levels of mitochondrial lipid PG led us to speculate if mitochondrial function is compromised in these isolates. Notably, a decrease accessibility of mito-tracker dye to TW17 cells as compared to TW1 cells provided sufficient evidence of compromised mitochondria (Figure 5); however, apparently the damage was restricted to mitochondrial membrane structure since it was not enough to cause respiratory defect and the accumulation of ROS (data not shown). This also supports an earlier observation that respiratory deficiency per se is not sufficient for eliciting MDR in yeast [43], [47].
There are examples to suggest a possible link between mitochondrial dysfunction, lipid homeostasis and CW integrity [25], [48]. Reportedly, S. cerevisiae and C. glabrata mitochondrial mutants most susceptible to caspofungin were those with impaired mitochondrial biosynthesis of the PLs namely PG and CL [25], [43], [49]–[51]. We observed that AR isolate TW17 that had lower levels of PG also possessed damaged CW as was evident from its sensitivity to CW disrupting agents and TEM images. Notably, we could also indirectly correlate CW damage and azole resistance with mitochondrial PG content by assessing CW damage in another set of matched pairs of AS and AR isolates. We observed that AR isolates which had lower PG content were also susceptible to CW disrupting agents as compared to those pairs which were resistant to azoles but showed no change in PG levels. We suspect that it is PG levels rather than CL that are more linked to mitochondrial defect and CW integrity. This notion is supported by a recent study, where it is demonstrated that nulls of PEL1 (encodes PG biosynthetic gene) in C. albicans have damaged CW and decreased susceptibility to FLC [52]. Notably, CL defects in mitochondrial membranes can easily be compensated for by PE, with the two PLs having overlapping roles [53]–[55]. Our MS and HP-TLC did not reveal any significant change in PE levels between these isolates (Figure 4). However, this was not reflected from our RT-PCR data analysis where both PSD1 and PSD2 (the phosphatidylserine decarboxylases that catalyze the conversion of PS to PE) were upregulated in TW17 isolate as compared with its susceptible counterpart (Table 1).
Notably, in certain matched clinical isolates (DSY775/DSY296) neither PG levels nor any defect in CW integrity was evident and yet these isolates displayed reduce susceptibility to FLC. It emphasizes the fact that that the development of MDR in C. albicans employs multiple pathways [5]–[8].
Although our data establishes a link between altered lipid homeostasis, mitochondrial dysfunction and CW integrity in the development of azole tolerance in C. albicans, how these events lead to the activation of MDR pathway is not clear. It has been shown that mitochondrial dysfunction can lead to the activation of Pdr pathway in S. cerevisiae [56]. The available evidence in S. cerevisiae points to a link between mitochondrial control over membrane structure and lipid homeostasis and the role of the Pdr pathway in membrane biogenesis [43], [57]–[59]. For example, deletion of ScOXA1 (a mitochondrial inner membrane insertase with cytochrome oxidase activity) results in increase drug resistance without any apparent loss in mtDNA [47], [59]. Loss of PGS1 (a phosphatidylglycerolphosphate synthase that catalyzes the synthesis of phosphatidylglycerolphosphate from CDP-diacylglycerol and sn-glycerol 3-phosphate) also results in decrease susceptibility to drugs independent of mtDNA loss [39], [57]–[61]. It is shown that in Psd1 in respiratory deficient yeast is partly dissociated and results in activation of MDR pathway [43], [62]. However, one needs to uncover regulatory pathway (s) interlinking CDR genes with mitochondrial functions in C. albicans.
Although it is not yet clear how and in which order these events are interlinked and triggered, but one could safely conclude that an extensive membrane remodeling and cellular lipid signaling is essential for the survival of azole stress and for the up-regulation of genes coding for multidrug transporters. Several recent studies have highlighted the importance of mitochondrial function for tolerance of antifungal drugs but the exact molecular mechanisms are not fully understood. Our study provides first clinical evidence wherein an interplay between mitochondria, CW and lipid homeostasis in the development of azole tolerance is evident.
Materials and Methods
Strains, media and culture conditions
C. albicans strains used in this study are listed in Table S4 [16], [17], [67], [68] and will be described as TW series of isolates throughout the study. C. albicans cells were kept on YPD plates and used to inoculate in YPD medium (1% yeast extract, 2% glucose, and 2% bactopeptone). For solid media, 2.5% agar was added. The cells were diluted into 50 ml fresh medium at 0.1 OD at A600 (∼106 cells/ml) and grown until the cells reached the density of ∼2×108 cells/ml at 30°C (approximately in 14 hrs). Three separate cultures of each Candida isolate were used.
Lipid standards
Synthetic lipids with FA compositions that are not found, or are of very low abundance in Candida, were used as internal standards. Lipid standards were obtained from Avanti Polar Lipids (Alabaster, AL).
Lipid Extraction
Lipids were extracted from Candida cells using a slight modification of the method of Bligh and Dyer [18]. Briefly, the Candida cells were harvested at exponential phase and were suspended in 10 ml methanol. 4 g glass beads (Glaperlon 0.40–0.60 mm) were added and the suspension was shaken in a cell disintegrator (B. Braun, Melsungen, Germany) four times for 30 sec with a gap of 30 sec between shakings. Approximately 20 ml chloroform was added to the suspension to give a ratio of 2∶1 of chloroform: methanol (v/v). The suspension was stirred on a flat-bed stirrer at room temperature for 2 hrs and then filtered through Whatman No. 1 filter paper. The extract was then transferred to a separating funnel and washed with 0.2 volumes of 0.9% NaCl to remove the non-lipid contaminants. The aqueous layer was aspirated and the solvent of the lipid-containing, lower organic layer was evaporated under N2. The lipids were stored at −80°C until they were analyzed.
ESI-MS/MS lipid profiling
An automated ESI-MS/MS approach was used to quantify PGL, SL and SE. Data acquisition and analysis was carried out as described previously by Devaiah et al. and Singh et al. [16], [26], [63]. Precise amounts of internal standards, obtained and quantified as previously described by Welti et al. and Singh et al. [16], [26], [64], were added. Processing of the data, including isotope deconvolution, was done similar to the way described by Singh et al. [16], [21]. For details, see Text S1.
High Performance – Thin Layer Chromatography (HP-TLC)
The Candida cells were grown overnight (to the exponential growth phase) in YEPD medium. Lipids were extracted as described earlier [18]. Following extraction samples were processed on the automated HP-TLC system (CAMAG, Muttenz, Switzerland) according to the instructions of the manufacturer. Ready-to-use silica coated plates (Merck) were activated in 80°C for 30–45 min. Sample volume equivalent to 120µg lipid was applied in band-form using specialized Hamilton syringe on one-side of the TLC plate in individual tracks. The TLC plate was developed in chloroform: methanol: acetic acid (65∶28∶8) solvent system. The plate was developed in the automated developing chamber (CAMAG) until the solvent front reached the maximum distance (80 mm distance in a typical 20×10 cm plate). The developed plate was dried and separated lipids were stained with iodine for visualization of various PLs. Then subsequent charring with 470 mM CuSO4 (in 8.5% o-phosphoric acid) was carried out. The individual Rf values of peaks along with their peak areas were obtained. These data were matched with the lipid standards.
Drug susceptibility
Drug susceptibilities were measured by using microtiter plate and spot assays. The MICs for the strains were determined with a broth microdilution method as described previously [15]. For the spot assay, 5-μl samples of fivefold serial dilutions of each yeast culture (each with cells suspended in normal saline to an optical density at 600 nm [OD600] of 0.1) were spotted onto YEPD plates in the absence (control) or in the presence of various concentrations of FLC. Growth differences were recorded following incubation of the plates for 48 h at 30°C.
Mitochondrial integrity
The integrity of mitochondria was determined using MitoTracker Red CMXRos (Molecular probes, Invitrogen). Briefly, cells (equal to 0.1 O.D) were stained with 100 nM MitoTracker Red CMXRos (which fluoresces upon oxidation in respiring mitochondria) at 30°C for 45 min. Flow cytometry of the stained cells was performed as described previously [23]. The red fluorescence of MitoTracker Red CMXRos was also visualized by confocal microscopy as described previously [23], [24].
CW susceptibility
Spot tests were performed (as described above) on YEPD plates in the absence (control) or in the presence of the following agents: SDS (0.02%), congo red (16 μg/ml) and calcofluor white (upto 50 μg/ml). The plates then incubated for 48 hrs at 30°C, recorded growth differences.
Membrane permeabilization assays
The permeability changes in Candida isolates was monitored by the impermeant dye PI (Propiduim Iodide). For this, C. albicans cells (∼1×106) were first harvested at the logarithmic phase and suspended in PBS (phosphate buffer saline). Cells were incubated in water bath set at 30°C at 200 rpm with 3.0 μM (PI) for 45 min. After incubation, cells were harvested by centrifugation. The aliquots of the cell suspension were taken in separate vials and then cells were re-suspended in PBS [65]. Flow cytometry was performed with a Calibur flow cytometer (Becton–Dickinson, San Jose, CA, USA). Further, the aliquots after PI treatments (those collected in flow cytometry experiment) were taken and the emission spectrum of PI was recorded for each strain using a fluorescence spectrophotometer (CARY-Eclipse, Varian Inc., Netherlands). The excitation and emission wavelengths used for PI were 536 and 617 nm respectively.
Reverse transcriptase – polymerase chain reaction (RT-PCR)
RNA isolation was done using RNeasy Mini Kit (QIAGEN Inc., USA) as per manufacturer's specifications, except that 300μl acid washed 0.4–0.6 mm glass beads (Sigma, St. Louis, MO) were used during cell lysis. RNA was precipitated using absolute ethanol and washed twice with 80% ethanol, dried and resuspended in 50 μl DEPC treated water at 58oC. RNA obtained was quantitated spectrophometrically and it was also electrophoresed in denaturing formaldehyde gel.
RT-PCR was done using the RevertAidTM H Minus kit (MBI, Fermentas). Briefly, 1µg isolated RNA was primed with oligo (dT)18 for cDNA syntheis at 42°C for 60 min. Reverse transcription reaction was terminated by heating at 70°C for 5 min. The synthesized cDNA product (2µl) was directly used for PCR amplification reaction (50 µl) using gene specific forward and reverse primers. The amplified products were subjected to gel electrophoresis and were quantitated by using Quantity One software with the Bio-Rad gel documentation system. The densities of bands (for genes of interest) were measured and normalized to that of the endogenous gene. The oligonucleotide sequences used for RT-PCR are listed in Sheet S2. Of note, our RT-PCR analysis included most of the responsive genes of lipid metabolism as was earlier detected from the microarray analysis of these isolates [66].
Statistical Analysis
The mean of three independent biological replicates ± standard deviation (SD) from the individual samples was used to compare the lipids of Candida strains. Multivariate data analysis (pattern recognition) was employed. PCA was performed using the software SYSTAT, version 10 (Systat Software Inc., Richmond, CA, USA) using three replicates of each of the AS and AR Candida isolate to highlight the statistically significant lipid differences. To assess the statistical significance of the difference in lipid datasets and PC scores, the Student t-test was performed using the significance level of 0.05. Hierarchical cluster analysis was also performed using SYSTAT, version 10. When all the values for a particular lipid species were zero in all samples, the data for that lipid species were removed from the analysis. The data in percentage were log-transformed and normalized to the same scale for PCA and hierarchical cluster analysis.
Supporting Information
Acknowledgments
We are thankful to Theodore C. White, Joachim Morschhäuser and Dominique Sanglard for generously providing C. albicans isolates used in this study. We acknowledge the help from Nitin Bhardwaj in flow cytometry analysis. We acknowledge AIRF, JNU for providing GC-MS and Confocal microscope and technical assistance therein by Ajay Kumar and Charu, respectively. We acknowledge Ram Rajasekharan and MM Gupta for providing HP-TLC facility at CIMAP, Lucknow.
Footnotes
Competing Interests: The authors have declared that no competing interests exist.
Funding: The work presented in this paper has been supported in part by grants to RP from the Department of Biotechnology (BT/PR11158/BRB/10/640/2008, BT/PR13641/Med/29/175/2010, BT/PR14879/BRB10/885/2010, BT/01/CEIB/10/III/02). The lipid analyses described in this work were performed at the Kansas Lipidomics Research Center Analytical Laboratory, where equipment acquisition and method development were funded by National Science Foundation (EPS 0236913, MCB 0455318, DBI 0521587), Kansas Technology Enterprise Corporation, K-IDeA Networks of Biomedical Research Excellence (INBRE) of National Institutes of Health (P20RR16475), the Johnson Cancer Center, and Kansas State University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005;56:i5–i11. doi: 10.1093/jac/dki218. [DOI] [PubMed] [Google Scholar]
- 2.Pfaller MA, Diekema DJ. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin Microbiol Rev. 2007;20:133–163. doi: 10.1128/CMR.00029-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis. 2002;15:569–574. doi: 10.1097/00001432-200212000-00003. [DOI] [PubMed] [Google Scholar]
- 4.Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, et al. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents. 2006;27:359–366. doi: 10.1016/j.ijantimicag.2006.01.002. [DOI] [PubMed] [Google Scholar]
- 5.Prasad R, Kapoor K. Multidrug resistance in yeast Candida. Int Rev Cytol. 2005;242:215–248. doi: 10.1016/S0074-7696(04)42005-1. [DOI] [PubMed] [Google Scholar]
- 6.White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998;11:382–402. doi: 10.1128/cmr.11.2.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Sanglard D, Coste A, Ferrari S. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res. 2009;9:1029–1050. doi: 10.1111/j.1567-1364.2009.00578.x. [DOI] [PubMed] [Google Scholar]
- 8.Sanglard D, White TC. Heitman J, Filler SG, Edwards JE, Mitchell AP, editors. Chapter 14 -Molecular Principles of Antifungal Drug Resistance. 2005. Molecular principles of fungal pathogenesis. Washington, D.C.: ASM Press.197–212.
- 9.Pasrija R, Panwar SL, Prasad R. Multidrug transporters CaCdr1p and CaMdr1p of Candida albicans display different lipid specificities: both ergosterol and sphingolipids are essential for targeting of CaCdr1p to membrane rafts. Antimicrob Agents Chemother. 2008;52:694–704. doi: 10.1128/AAC.00861-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Mukhopadhyay K, Prasad T, Saini P, Pucadyil TJ, Chattopadhyay A, et al. Membrane Sphingolipid- Ergosterol interactions are important determinants of Multidrug Resistance in Candida albicans. Antimicrob Agents Chemother. 2004;48:1778–1787. doi: 10.1128/AAC.48.5.1778-1787.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Pasrija R, Prasad T, Prasad R. Membrane raft lipid constituents affect drug susceptibilities of Candida albicans. Biochem Soc Trans. 2005;33:1219–1223. doi: 10.1042/BST20051219. [DOI] [PubMed] [Google Scholar]
- 12.Morschhauser J. The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta. 2002;1587:240–248. doi: 10.1016/s0925-4439(02)00087-x. [DOI] [PubMed] [Google Scholar]
- 13.Marie C, White TC. Genetic Basis of Antifungal Drug Resistance. Curr Fungal Infect Rep. 2009;3:163–169. doi: 10.1007/s12281-009-0021-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Kohli A, Smriti, Mukhopadhyay K, Rattan A, Prasad R. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob Agents Chemother. 2002;46:1046–1052. doi: 10.1128/AAC.46.4.1046-1052.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Mukhopadhyay K, Kohli A, Prasad R. Drug susceptibilities of yeast cells are affected by membrane lipid composition. Antimicrob Agents Chemother. 2002;46:3695–3705. doi: 10.1128/AAC.46.12.3695-3705.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Singh A, Prasad R. Comparative lipidomics of azole sensitive and resistant clinical isolates of Candida albicans reveals unexpected diversity in molecular lipid imprints. PLoS One 29. 2011;6(4):e19266. doi: 10.1371/journal.pone.0019266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.White TC. Increased mRNA Levels of ERG16, CDR, and MDR1 Correlate with Increases in Azole Resistance in Candida albicans Isolates from a Patient Infected with Human Immunodeficiency Virus. Antimicrob Agents Chemother. 1997;41:1482–1487. doi: 10.1128/aac.41.7.1482. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
- 19.Han X, Gross RW. Electrospray ionization mass spectroscopic analysis of human erythrocyte plasma membrane phospholipids. Proc Natl Acad Sci USA 91: 10635– 10639. 1994. [DOI] [PMC free article] [PubMed]
- 20.Shevchenko A, Simons K. Lipidomics: coming to grips with lipid diversity. Nat Rev Mol Cell Biol. 2010;11:593–598. doi: 10.1038/nrm2934. [DOI] [PubMed] [Google Scholar]
- 21.Singh A, Prasad T, Kapoor K, Mandal A, Roth M, et al. Phospholipidome of Candida: each species of Candida has distinctive phospholipid molecular species. OMICS. 2010;14:665–677. doi: 10.1089/omi.2010.0041. [DOI] [PubMed] [Google Scholar]
- 22.Schlame M, Rua D, Greenberg ML. The biosynthesis and functional role of cardiolipin. Prog Lipid Res. 2000;39:257–288. doi: 10.1016/s0163-7827(00)00005-9. [DOI] [PubMed] [Google Scholar]
- 23.Oliver BG, Silver PM, Marie C, Hoot SJ, Leyde SE, et al. Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiol. 2008;154:960–970. doi: 10.1099/mic.0.2007/013805-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Orij R, Postmus J, Beek AT, Brul S, Smits GJ. In vivo measurement of cytosolic and mitochondrial pH using a pH-sensitive GFP derivative in Saccharomyces cerevisiae reveals a relation between intracellular pH and growth. Microbiol. 2009;155:268–278. doi: 10.1099/mic.0.022038-0. [DOI] [PubMed] [Google Scholar]
- 25.Dagley MJ, Gentle IE, Beilharz TH, Pettolino FA, Djordjevic JT, et al. Cell wall integrity is linked to mitochondria and phospholipid homeostasis in Candida albicans through the activity of the post-transcriptional regulator Ccr4-Pop2. Mol Microbiol. 2011;79:968–989. doi: 10.1111/j.1365-2958.2010.07503.x. [DOI] [PubMed] [Google Scholar]
- 26.van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9:112–124. doi: 10.1038/nrm2330. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Simons K. Model Systems, Lipid Rafts, and Cell Membranes. Annu Rev Biophys Biomol Struct. 2004;33:269–295. doi: 10.1146/annurev.biophys.32.110601.141803. [DOI] [PubMed] [Google Scholar]
- 28.Zhang Y-Q, Gamarra S, Garcia-Effron G, Park S, Perlin DS, et al. Requirement for Ergosterol in V-ATPase Function Underlies Antifungal Activity of Azole Drugs. PLoS Pathog 6(6): e1000939. 2010. doi:10.1371/journal.ppat.1000939. [DOI] [PMC free article] [PubMed]
- 29.Tate CG. Overexpression of mammalian integral membrane proteins for structural studies. FEBS Lett. 2001;504:94–98. doi: 10.1016/s0014-5793(01)02711-9. [DOI] [PubMed] [Google Scholar]
- 30.Klappe K, Dijkhuis AJ, Hummel I, van Dam A, Ivanova PT, et al. Extensive sphingolipid depletion does not affect lipid raft integrity or lipid raft localization and efflux function of the ABC transporter MRP1. Biochem J. 2010;430:519–529. doi: 10.1042/BJ20091882. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.DiRusso CC, Black PN. Long-chain fatty acid transport in bacteria and yeast. Paradigms for defining the mechanism underlying this protein-mediated process. Mol Cell Biochem. 1999;192:41–52. [PubMed] [Google Scholar]
- 32.DiRusso CC, Black PN. Bacterial Long Chain Fatty Acid Transport: Gateway to a Fatty Acid-responsive Signaling System. J Biol Chem. 2004;279:49563–49566. doi: 10.1074/jbc.R400026200. [DOI] [PubMed] [Google Scholar]
- 33.Janmey PA, Kinnunen PKJ. Biophysical properties of lipids and dynamic membranes. Trends Cell Biol. 2006;16:538–546. doi: 10.1016/j.tcb.2006.08.009. [DOI] [PubMed] [Google Scholar]
- 34.Helmreich EJM. Environmental influences on signal transduction through membranes: a retrospective mini-review. Biophys Chem. 2003;100:519–534. doi: 10.1016/s0301-4622(02)00303-4. [DOI] [PubMed] [Google Scholar]
- 35.Baylin A, Kim MK, Donovan-Palmer A, Siles X, Dougherty L, et al. Fasting Whole Blood as a Biomarker of Essential Fatty Acid Intake in Epidemiologic Studies: Comparison with Adipose Tissue and Plasma. Am J Epidemiol. 2005;162:373–381. doi: 10.1093/aje/kwi213. [DOI] [PubMed] [Google Scholar]
- 36.Řezanka T, Sigler K. Odd-numbered very-long-chain fatty acids from the microbial, animal and plant kingdoms. Prog Lipid Res. 2009;48:206–238. doi: 10.1016/j.plipres.2009.03.003. [DOI] [PubMed] [Google Scholar]
- 37.Fievez V, Colman E, Castro-Montoya JM, Stefanov I, Vlaeminck B. Milk odd- and branched-chain fatty acids as biomarkers of rumen function–An update. 2011. doi.org/10.1016/j.anifeedsci.2011.12.008.
- 38.Millar AA, Wrischer M, Kunsta L. Accumulation of Very-Long-Chain Fatty Acids in Membrane Glycerolipids Is Associated with Dramatic Alterations in Plant Morphology. The Plant Cell. 1998;11:1889–1902. doi: 10.1105/tpc.10.11.1889. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Zhong Q, Gvozdenovic-Jeremic J, Webster P, Zhou J, Greenberg ML. Loss of Function of KRE5 Suppresses Temperature Sensitivity of Mutants Lacking Mitochondrial Anionic Lipids. Mol Biol Cell. 2005;16:665–675. doi: 10.1091/mbc.E04-09-0808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Ferrari S, Ischer F, Calabrese D, Posteraro B, Sanguinetti M, et al. Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence. PLoS Pathog 5(1): e1000268. 2009. doi:10.1371/journal.ppat.1000268. [DOI] [PMC free article] [PubMed]
- 41.Ferrari S, Sanguinetti M, Bernardis FD, Torelli R, Posteraro B, et al. Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice. Antimicrob Agents Chemother. 2011;55:1852–1860. doi: 10.1128/AAC.01271-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Osman C, Voelker DR, Langer T. Making heads or tails of phospholipids in mitochondria. J Cell Biol. 2011;192:7–16. doi: 10.1083/jcb.201006159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Shingu-Vazquez M, Traven A. Mitochondria and Fungal Pathogenesis: Drug Tolerance, Virulence, and Potential for Antifungal Therapy. Eukaryot Cell. 2011;10:1376–1383. doi: 10.1128/EC.05184-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Cheng S, Clancy CJ, Nguyen KT, Clapp W, Nguyen MH. A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole. Antimicrob Agents Chemother. 2007;51:1855–1858. doi: 10.1128/AAC.00182-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Kaur R, Castano I, Cormack BP. Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob Agents Chemother. 2004;48:1600–1613. doi: 10.1128/AAC.48.5.1600-1613.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Tsai HF, Krol AA, Sarti KE, Bennett JE. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Chemother. 2006;50:1384–1392. doi: 10.1128/AAC.50.4.1384-1392.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Zhang X, Moye-Rowley WS. Saccharomyces cerevisiae multidrug resistance gene expression inversely correlates with the status of the F(0) component of the mitochondrial ATPase. J Biol Chem. 2001;276:47844–47852. doi: 10.1074/jbc.M106285200. [DOI] [PubMed] [Google Scholar]
- 48.Chen YL, Montedonico AE, Kauffman S, Dunlap JR, Menn FM, et al. Phosphatidylserine synthase and phosphatidylserine decarboxylase are essential for cell wall integrity and virulence in Candida albicans. Mol Microbiol. 2010;75:1112–1132. doi: 10.1111/j.1365-2958.2009.07018.x. [DOI] [PubMed] [Google Scholar]
- 49.Kornmann B, Currie E, Collins SR, Schuldiner M, Nunnari J, et al. An ER-mitochondria tethering complex revealed by a synthetic biology screen. Science. 2009;325:477–481. doi: 10.1126/science.1175088. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Osman C, Haag M, Potting C, Rodenfels J, Dip PV, et al. The genetic interactome of prohibitins: coordinated control of cardiolipin and phosphatidylethanolamine by conserved regulators in mitochondria. J Cell Biol. 2009;184:583–596. doi: 10.1083/jcb.200810189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Tamura Y, Endo T, Iijima M, Sesaki H. Ups1p and Ups2p antagonistically regulate cardiolipin metabolism in mitochondria. J Cell Biol. 2009;185:1029–1045. doi: 10.1083/jcb.200812018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Thomas E, Panwar SL, Ansari HR. PEL1 (Phosphatidylglycerol Phosphate Synthase) is required for mitochondrial function and affects drug susceptibility in C. albicans. In: Human Fungal Pathogens Molecular Mechanism of Host-Pathogen Interactions and Virulence, 4th FEBS Advanced Lecture Course, La Colle sur Loup, France. Abstract P3–15C. 2011.
- 53.Gohil VM, Thompson MN, Greenberg ML. Synthetic Lethal Interaction of the Mitochondrial Phosphatidylethanolamine and Cardiolipin Biosynthetic Pathways in Saccharomyces cerevisiae. J Biol Chem. 2005;280:35410–35416. doi: 10.1074/jbc.M505478200. [DOI] [PubMed] [Google Scholar]
- 54.Mileykovskaya E, Sun Q, Margolin W, Dowhan W. Localization and Function of Early Cell Division Proteins in Filamentous Escherichia coli Cells Lacking Phosphatidylethanolamine. J Bacteriol. 1998;180:4252–4257. doi: 10.1128/jb.180.16.4252-4257.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Li G, Chen S, Thompson MN, Greenberg ML. New insights into the regulation of cardiolipin biosynthesis in yeast: Implications for Barth syndrome. Biochim Biophys Acta – Mol Cell Biol Lipids. 2007;1771:432–441. doi: 10.1016/j.bbalip.2006.06.007. [DOI] [PubMed] [Google Scholar]
- 56.Shahi P, Moye-Rowley WS. Coordinate control of lipid composition and drug transport activities is required for normal multidrug resistance in fungi. Biochim Biophys Acta. 2009;1794:852–859. doi: 10.1016/j.bbapap.2008.12.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Birner R, Daum G. Biogenesis and cellular dynamics of aminoglycerophospholipids. Int Rev Cytol. 2003;225:273–323. doi: 10.1016/s0074-7696(05)25007-6. [DOI] [PubMed] [Google Scholar]
- 58.Burgermeister M, Birner-Grunberger R, Nebauer R, Daum G. Contribution of different pathways to the supply of phosphatidylethanolamine and phosphatidylcholine to mitochondrial membranes of the yeast Saccharomyces cerevisiae. Biochim Biophys Acta. 2004;1686:161–168. doi: 10.1016/j.bbalip.2004.09.007. [DOI] [PubMed] [Google Scholar]
- 59.Voelker DR. Interorganelle transport of aminoglycerophospholipids. Biochim Biophys Acta. 2000;1486:97–107. doi: 10.1016/s1388-1981(00)00051-2. [DOI] [PubMed] [Google Scholar]
- 60.Hallstrom TC, Moye-Rowley WS. Multiple signals from dysfunctional mitochondria activate the pleiotropic drug resistance pathway in Saccharomyces cerevisiae. J Biol Chem. 2000;275:37347–37356. doi: 10.1074/jbc.M007338200. [DOI] [PubMed] [Google Scholar]
- 61.Batova M, Borecka-Melkusova S, Simockova M, Dzugasova V, Goffa E, et al. Functional characterization of the CgPGS1 gene reveals a link between mitochondrial phospholipid homeostasis and drug resistance in Candida glabrata. Curr Genet. 2008;53:313–322. doi: 10.1007/s00294-008-0187-9. [DOI] [PubMed] [Google Scholar]
- 62.Gulshan K, Schmidt JA, Shahi P, Moye-Rowley WS. Evidence for the bifunctional nature of mitochondrial phosphatidylserine decarboxylase: role in Pdr3-dependent retrograde regulation of PDR5 expression. Mol Cell Biol. 2008;28:5851–5864. doi: 10.1128/MCB.00405-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Devaiah SP, Roth MR, Baughman E, Li M, Tamura P, et al. Quantitative profiling of polar glycerolipid species from organs of wild-type Arabidopsis and a phospholipase Dalpha1 knockout mutant. Phytochemistry. 2006;67:1907–1924. doi: 10.1016/j.phytochem.2006.06.005. [DOI] [PubMed] [Google Scholar]
- 64.Welti R, Li W, Li M, Sang Y, Biesiada H, et al. Profiling membrane lipids in plant stress responses. Role of phospholipase D alpha in freezing-induced lipid changes in Arabidopsis. J Biol Chem. 2002;277:31994–32002. doi: 10.1074/jbc.M205375200. [DOI] [PubMed] [Google Scholar]
- 65.Moore A, Donahue CJ, Bauer KD, Mather JP. Simultaneous measurement of cell cycle and apoptotic cell death. Meth Cell Biol. 1998;57:265–278. doi: 10.1016/s0091-679x(08)61584-8. [DOI] [PubMed] [Google Scholar]
- 66.Liu TT, Znaidi S, Barker KS, Xu L, Homayouni R, et al. Genome-Wide Expression and Location Analyses of the Candida albicans Tac1p Regulon. Eukaryot Cell. 2007;6:2122–2138. doi: 10.1128/EC.00327-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Franz R, Ruhnke M, Morschhauser J. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses. 1999;42:453–458. doi: 10.1046/j.1439-0507.1999.00498.x. [DOI] [PubMed] [Google Scholar]
- 68.Karababa M, Coste AT, Rognon B, Bille J, Sanglard D. Comparison of Gene Expression Profiles of Candida albicans Azole-Resistant Clinical Isolates and Laboratory Strains Exposed to Drugs Inducing Multidrug Transporters. Antimicrob Agents Chemother. 2004;48:3064–3079. doi: 10.1128/AAC.48.8.3064-3079.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.